Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

SAXAPCOS

Novo Nordisk · Phase 3 · Completed · Enrollment 88

NCT03480022

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Liraglutide Pen Injector (Saxenda)n/rn/rn/rn/r
Placebo liraglutide pen injectorn/rn/rn/rn/r

Not shown

  • Liraglutide Pen Injector (Saxenda): endpoint not reported
  • Placebo liraglutide pen injector: endpoint not reported